血液科

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. A Study of the Safety, Tolerability, Drug/Body Interactions, Biological and Clinical Activity of MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to assess the safety, tolerability, drug/body interactions, and the biological and clinical activities of MSB0011359C (M7824) at different dose levels given to patients who have metastatic or locally advanced solid tumors.

2. Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other places in the body, does not respond to treatment, or cannot be surgically removed. Drugs such as sapanisertib may stop the growth or shrink tumor cells by blocking some of the enzymes needed for cell growth

3. International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

   Rochester, Minn.

   This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment. The study design has evolved from lengthy international consultation that has enabled us to build consensus over which questions arise from current knowledge and practice. It will enable potential randomisation for the majority of patients with inguinal lymph node metastases and will provide data to inform future clinical decisions. InPACT-neoadjuvant patients are stratified by disease burden as assessed by radiological criteria. Treatment options are then defined according to the disease burden strata. Treatment is allocated by randomisation. Patients may be allocated to one of three initial treatments: A. standard surgery (ILND); B. neoadjuvant chemotherapy followed by standard surgery (ILND); or C. neoadjuvant chemoradiotherapy followed by standard surgery (ILND). After ILND, patients are defined as being at low or high risk of recurrence based on histological interpretation of the ILND specimen. Patients at high risk of relapse are eligible for InPACT-pelvis, where they are randomised to either: P. prophylactic PLND Q. no prophylactic PLND

4. A Study to Evaluate VSV-hIFNbeta-NIS to Treat Patients with Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, or T-cell Lymphoma

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter [NIS]) in treating patients with multiple myeloma, acute myeloid leukemia, or T-cell lymphoma that has come back or does not respond to treatment. A virus, called VSV-hIFNbeta-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells.

5. Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

   Rochester, Minn.

   This clinical trial is studying long-term follow-up in patients who are or have participated in Children's Oncology Group studies. Developing a way to track patients enrolled in Children's Oncology Group studies will help doctors gather long-term follow-up information and may help the study of cancer in the future.

6. A Study to Provide Access to CTL019 Out of Specification Managed Access Program (MAP) for ALL or DLBCL Patients

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.

7. A Study to Evaluate the Safety and Effectiveness of ALLO-501A CAR T Cell Therapy in Adults with Relapsed/ Refractory Large B Cell Lymphoma

   Scottsdale/Phoenix, Ariz.

   The primary purpose of this study is to assess the safety and effectiveness of ALLO-501A to treat patients with relapsed/refractory large B cell lymphoma (LBCL) to determine the maximum tolerated dose (MTD).

8. A Study of Cell, Serum, and Bone Marrow Bank for Patients receiving Chimeric Antigen Receptor T Cell Therapy for the Treatment of Cancer

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to store blood, serum and bone marrow so that they can be used for laboratory studies that may contribute to finding the exact function of the CART cells or T-cell engager therapy such as bispecific and trispecific antibodies and the factors that may determine disease progression and treatment response.

9. Trimethoprim-sulfamethoxazole Graded Administration in Oncology, Hematopoietic Stem Cell Transplant, and Solid Organ Transplant Patients with a History of Sulfonamide Allergy

   Rochester, Minn.

   The aim of this study is to study the efficacy and safety of our short and long one-day protocols for TMP-SMX graded administration in hematologic malignancy, hematopoietic stem cell transplant, and solid organ transplant patients.    

10. Exploring Mechanisms of Action and Resistance of Therapeutic Agents in Patients with B-cell Malignancies

    Jacksonville, Fla.

    This study is being performed to understand the causes of drug resistance and to improve the treatment options for patients diagnosed with B-cell cancers. We aim to identify the reasons why certain therapies work and others don’t and as result- develop new treatments for blood cancers.